Moderna (MRNA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Moderna (MRNA)

47.44

-4.15 (8.04%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

142 watching

Investor Insights

Jun 5, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Moderna (MRNA-Q) has shown a significant turnaround in performance, with a remarkable increase of 72% in Q1, bolstered by the resolution of some lawsuits that had previously weighed on the company. The FDA approval of its new flu vaccine is another positive development, especially with impending changes in regulatory leadership that may favor its future endeavors. However, while the stock saw a nearly 50% rally last month, there are concerns about its long-term profitability and reliance on returning to revenue growth by 2026. The biotech market's binary nature adds uncertainty, leading some experts to question whether Moderna can effectively leverage its technology in adjacent markets. Overall, the sentiment around Moderna is mixed, with potential for growth but also significant risks involved.

Consensus

Mixed

Valuation

Fair Value

Similar

Pfizer, PFE

BUY

They report next week. Not sure how it'll pay out because of the slower uptake of their 4th booster shot, but they have an incredible pipeline.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Jul 07/22, Down 30.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRNA has triggered its stop at $120. To remain disciplined, we recommend covering the position at this time.

COMMENT

It has suffered enough. A well-run company, but shares can fall lower. Enough is enough.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly Trading at only 5x earnings, this is one of the least expensive stocks in the S&P500. The company is looking to expand its COVID vaccine in Europe and the US for children under 6 years. Recently reported earnings smashed analyst expectations by over 65% and is generating a ROE over 120%. The company has been prudently using a small portion of cash reserves to help aggressively buy back shares and retire debt. We recommend a stop loss at $120, looking to achieve $228 -- upside potential over 42%. Yield 0% (Analysts’ price target is $228.00)

BUY

Biotechs have strong balance sheets, better than a few years ago. Likes this as well as Amgen. Better to buy individual biotech stocks over ETFs.

BUY

Has lightened his holding (and all his stocks) because of this market, but it remains one of the cheapest stocks out there with a lot of cash in order to buy another company. Their drug pipeline continues to grow. It's the best biotech out there.

DON'T BUY

Chart has come full circle. Covid vaccine was a tremendous short-term win for the company and society. Revenues are trailing off for the next 2 years. Avoid the rockets and torpedoes. Look at PFE instead.

COMMENT

They report Wednesday. They made a lot of cash during the pandemic, but they need to expand and can't be a one-trick pony. Need to broaden their portfolio.

BUY ON WEAKNESS

Shares are plunging today. They sold over $18 billion of vaccines for 2022. All vaccine stocks have fallen for the same reason: Covid is ending. He's short calls and long puts for Moderna (has been so for many months). Post-vaccine world, he thinks this will be the most-valuable healthcare company, because they have a platform that's grown from 21 therapeutics and vaccines to over 40 in the span of a year. The future is extremely bright. But biotech stocks are event-driven. So, no events, then shorting happens and sellers get impatient.

WATCH

It made a ton of money since Covid, but it hasn't done much with that cash and didn't develop a pill treatment like Pfizer. He wishes they would buy weaker biotechs with that cash to grow. He expects/hope that.

DON'T BUY

Fallen a lot recently. If we believe that Covid becomes endemic and we don't all need shots, what's going to happen to MRNA? Crazy cheap at 8-9x next year's earnings, beautiful balance sheet, technology works, but what's the next catalyst? He tends to stay away from biotechs and pharmas, as the science is too hard to understand.

COMMENT

Among the 10 top performers on the S&P of 2021 #3, up 143%. He doubts MRNA can repeat this increase unless everybody gets a fourth dose of their vaccine or can diversify into, say, cancer vaccines. He loves management, but the stock isn't pricing in the chance the Omicron will come and go quickly (and result in a bad kind of herd immunity).

BUY

Believes Moderna is example of how pharmaceuticals changing (increased vaccine turnaround time). Good buying opportunity at current price. Strong pipeline in many different areas. Opportunity to use Covid-19 education towards other diseases/viruses.

Premium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

One of the best drug pipeline in the industry and trading under 10x earnings according to Stephen Weiss. Social media mentions are up 1056% over the last 7 days.

DON'T BUY

Got hammered today, but they need to prove they can deliver vaccines to market.

Showing 31 to 45 of 64 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Moderna (MRNA)

Moderna(MRNA)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Moderna(MRNA)

Moderna(MRNA)

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

Moderna(MRNA)

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Moderna(MRNA)

Moderna(MRNA)

Moderna (MRNA) Frequently Asked Questions

What is Moderna stock symbol?

Is Moderna a buy or a sell?

Is Moderna a good investment or a top pick?

Why is Moderna stock dropping?

Is Moderna worth watching?

What is Moderna stock price?

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Brian Madden

The Panic-Proof Portfolio (Stockchase Research)

Darren Sissons

The Weekly Buzzing Stocks by Billy Kawasaki

Joe Terranova